[CAS NO. 548-73-2] Droperidol
PRODUCTS SPECIFICATIONS [548-73-2]
DESCRIPTION [548-73-2]
Overview
| MDL | MFCD00083290 |
|---|---|
| Molecular Weight | 379.43 |
| Molecular Formula | C22H22FN3O2 |
| SMILES | O=C1NC2=CC=CC=C2N1C3=CCN(CCCC(C4=CC=C(F)C=C4)=O)CC3 |
1 Publications Citing Use of MCE
Summary
Droperidol is a Dopamine-2 Receptor Antagonist. Target: D2DR Droperidol is a butyrophenone, with anti-emetic, sedative and anti-anxiety properties.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01942343 | University Hospital, Strasbourg, France |
Akathisia
|
October 2013 | Phase 3 |
| NCT02625181 | Vanderbilt University|Vanderbilt University Medical Center |
Postoperative Nausea and Vomiting
|
July 2016 | Not Applicable |
| NCT03023462 | Ostfold Hospital Trust |
Inguinal Hernia|Pain, Postoperative
|
September 5, 2019 | Not Applicable |
| NCT03944681 | Medical University of Gdansk |
Arrhythmia, Droperidol
|
April 23, 2019 | Not Applicable |
| NCT05244460 | Mercy Health Ohio|Lake Erie College of Osteopathic Medicine |
Cannabis Hyperemesis Syndrome
|
December 2, 2021 | Phase 3 |
| NCT02282956 | Dr.med. Sabine Schoenfeld|Spitalregion Rheintal, Werdenberg, Sarganserland |
Hallux Valgus
|
October 2014 | Phase 4 |
| NCT01434017 | Centre Hospitalier Universitaire Vaudois |
Postoperative Nausea and Vomiting
|
November 2008 | Phase 4 |
| NCT00624208 | University of British Columbia|British Columbia Childrens Hospital Foundation |
Myocardial Repolarization
|
February 2008 | Not Applicable |
| NCT00702442 | Aristotle University Of Thessaloniki|AHEPA University Hospital |
Vomiting
|
June 2008 | Phase 4 |
| NCT01406860 | University of Iowa |
Primary Headaches (Includes Migraines, Tension, Cluster Headaches)
|
July 2011 | Not Applicable |
| NCT02744495 | Hôpital Privé de Parly II - Le Chesnay |
Postoperative Vomiting|Postoperative Nausea|Postoperative Emesis
|
February 2016 | Phase 3 |
| NCT05065567 | Spectrum Health - Lakeland |
Cyclic Vomiting Syndrome
|
August 30, 2021 | Phase 2 |
| NCT02600741 | Janssen Scientific Affairs, LLC |
Schizophrenia
|
July 24, 2015 | |
| NCT05401058 | RenJi Hospital |
Digestive System Disease|Urologic Diseases|Gynecological Disease|Orthopedic Surgery
|
October 10, 2022 | Not Applicable |
| NCT01739985 | Assistance Publique - Hôpitaux de Paris |
Postoperative Vomiting
|
December 2010 | Not Applicable |
| NCT04411069 | Instituto do Cancer do Estado de São Paulo |
Postoperative Nausea|Postoperative Vomiting
|
February 20, 2019 | Phase 2 |
| NCT00445055 | University Hospital, Bordeaux|Prostrakan Pharmaceuticals |
Nausea|Vomiting
|
April 2007 | Phase 4 |
| NCT00209885 | Hvidovre University Hospital |
Cholecystolithiasis
|
October 2005 | Phase 4 |
| NCT02078336 | Universitaire Ziekenhuizen KU Leuven |
Dental Care for Disabled
|
December 2013 | Phase 4 |
| NCT01679093 | University Hospital, Lille |
Interaction Between Antiemetic Drugs and Paracetamol
|
June 2009 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 263.55 mM )
H 2 O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6355 mL | 13.1777 mL | 26.3553 mL |
| 5 mM | 0.5271 mL | 2.6355 mL | 5.2711 mL |
| 10 mM | 0.2636 mL | 1.3178 mL | 2.6355 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.59 mM); Clear solution
Synonyms